Search
D2C7 immunotoxin
go.drugbank.com/drugs/DB17540InvestigationalD2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas). … D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.
Ethanolamine
go.drugbank.com/drugs/DB03994InvestigationalA viscous, hygroscopic amino alcohol with an ammoniacal odor. It is widely distributed in biological tissue and is a component of lecithin.
Botulinum toxin type B
go.drugbank.com/drugs/DB00042ApprovedThe protein exists in noncovalent association with hemagglutinin and nonhemagglutinin proteins as a neurotoxin complex. … The neurotoxin complex is recovered from the fermentation process and purified through a series of precipitation and chromatography steps.
Categories: Complex MixturesNamilumab
go.drugbank.com/drugs/DB13037InvestigationalNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
Diprenorphine
go.drugbank.com/drugs/DB01548IllicitInvestigationalVet approvedA narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]
Citicoline
go.drugbank.com/drugs/DB12153ApprovedInvestigationalWithdrawnCiticoline is a donor of choline in biosynthesis of choline-containing phosphoglycerides.
Ditazole
go.drugbank.com/drugs/DB08994ApprovedWithdrawnAdditionally, ditazole is a platelet aggregation inhibitor marketed in Spain and Portugal with trade name Ageroplas.
RDP58
go.drugbank.com/drugs/DB06566ExperimentalRDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression of inflammatory cytokines.
SLx-4090
go.drugbank.com/drugs/DB05678InvestigationalSLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes.
IDM-4
go.drugbank.com/drugs/DB05438ExperimentalIDM-4 is an immuno-designed molecule that completed phase I/II of investigation for the treatment of Leukemia.